Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 709.46M | 1.37B | 1.93B | 974.51M | 1.01B |
| Total Depreciation and Amortization | 4.73B | 4.79B | 4.83B | 4.80B | 4.82B |
| Total Amortization of Deferred Charges | 265.19M | 219.53M | 219.53M | 219.53M | 219.53M |
| Total Other Non-Cash Items | 1.60B | 972.67M | 553.62M | 805.07M | 702.89M |
| Change in Net Operating Assets | -355.76M | 25.39M | -1.68B | -1.46B | -1.84B |
| Cash from Operations | 6.96B | 7.38B | 5.85B | 5.34B | 4.92B |
| Capital Expenditure | -1.32B | -1.30B | -1.32B | -1.25B | -1.22B |
| Sale of Property, Plant, and Equipment | 515.30K | 318.80K | 2.08M | 59.52M | 59.54M |
| Cash Acquisitions | -6.59M | -- | -- | -- | -- |
| Divestitures | 513.90M | 195.38M | 187.12M | 150.82M | 134.66M |
| Other Investing Activities | -1.59B | -1.58B | -1.30B | -1.31B | -2.26B |
| Cash from Investing | -2.40B | -2.68B | -2.43B | -2.35B | -3.29B |
| Total Debt Issued | 1.05T | 1.02T | 1.15T | 674.64B | 377.00B |
| Total Debt Repaid | -1.37T | -1.15T | -732.18B | -342.88B | -375.49B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -51.86B | -1.88B | -1.88B | -1.88B | -2.33B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.97B | -1.96B | -1.95B | -1.95B | -2.01B |
| Other Financing Activities | -82.75B | -79.00B | -72.36B | -15.58B | -66.42B |
| Cash from Financing | -4.99B | -3.40B | 234.87M | 1.59M | -2.45B |
| Foreign Exchange rate Adjustments | -84.27M | 50.52M | -120.61M | 188.20M | 185.26M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 6.90K | -400.00 |
| Net Change in Cash | -517.05M | 1.34B | 3.53B | 3.18B | -630.34M |